Evidence map›Paper›PMID 36969022›Full record

ArticleFrontiers in oncology2023

Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunities.

Aurelio Cruz-Valdez, Lina Sofia Palacio-Mejía, Amado D Quezada-Sánchez, Juan Eugenio Hernández-Ávila, Tatiana Galicia-Carmona, Lucely Del Carmen Cetina-Pérez, Eder A Arango-Bravo, David Isla-Ortiz, Carlos E Aranda-Flores, Santos-Regino Uscanga-Sánchez and 2 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Liquid Biopsy Biomarkers for Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Aurelio Cruz-ValdezCenter for Population Health Research, Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Lina Sofia Palacio-MejíaConsejo Nacional de Ciencia y Tecnología (CONACYT)-Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Amado D Quezada-SánchezCenter for Evaluation and Surveys Research, Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Juan Eugenio Hernández-ÁvilaCenter for Evaluation and Surveys Research, Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Tatiana Galicia-CarmonaDepartment of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico.
Lucely Del Carmen Cetina-PérezDepartment of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico.
Eder A Arango-BravoDepartment of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico.
David Isla-OrtizDepartment of Oncology Gynecology, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico.
Carlos E Aranda-FloresOncology Department, Hospital General de México "Eduardo Liceaga", Mexico City, Mexico.
Santos-Regino Uscanga-SánchezGynecologist Oncologist of MAGNI Gineco-Obstetras S.C, Mexico City, Mexico.
Vicente Madrid-MarinaChronic Infections and Cancer Division, Center for Research on Infectious Diseases, Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Kirvis Torres-PovedaConsejo Nacional de Ciencia y Tecnología (CONACYT)-Instituto Nacional de Salud Pública (INSP), Cuernavaca, Mexico.
Instituto Nacional de Salud Pública · MXInstituto Nacional de Cancerología · MXConsejo Nacional de Humanidades, Ciencias y Tecnologías · MXHospital General de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The COVID-19 pandemic disrupted the preventive services for cervical cancer (CC) control programs in Mexico, which will result in increased mortality. This study aims to assess the impact of the pandemic on the interruption of three preventive actions in the CC prevention program in Mexico. Methods: This study is a retrospective time series analysis based on administrative records for the uninsured population served by the Mexican Ministry of Health. Patient data were retrieved from the outpatient service information system and the hospital discharge database for the period 2017-2021. Data were aggregated by month, distinguishing a pre-pandemic and a pandemic period, considering April 2020 as the start date of the pandemic. A Poisson time series analysis was used to model seasonal and secular trends. Five process indicators were selected to assess the disruption of the CC program, these were analyzed as monthly data (N=39 pre-pandemic, N=21 during the pandemic). HPV vaccination indicators (number of doses and coverage) and diagnostic characteristics of CC cases were analyzed descriptively. The time elapsed between diagnosis and treatment initiation in CC cases was modeled using restricted cubic splines from robust regression. Results: Annual HPV vaccination coverage declined dramatically after 2019 and was almost null in 2021. The number of positive Papanicolaou smears decreased by 67.8% (90%CI: -72.3, -61.7) in April-December 2020, compared to their expected values without the pandemic. The immediate pandemic shock (April 2020) in the number of first-time and recurrent colposcopies was -80.5% (95%CI:-83.5, -77.0) and -77.9% (95%CI: -81.0, -74.4), respectively. An increasing trend was observed in the proportion of advanced stage and metastatic CC cases. The fraction of CC cases that did not receive medical treatment or surgery increased, as well as CC cases that received late treatment after diagnosis. Conclusions: Our analyses show significant impact of the COVID-19 pandemic with declines at all levels of CC prevention and increasing inequalities. The restarting of the preventive programs against CC in Mexico offers an opportunity to put in place actions to reduce the disparities in the burden of disease between socioeconomic levels.

Indexed as

COVID-19health impact assessmentMexicoprevention and controltime series analysisuterine cervical neoplasm

Identifiers

PMID36969022
PMCPMC10034019
OpenAlexW4323668036

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read3
measurements read152
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.